🚀 VC round data is live in beta, check it out!
Novogene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Novogene and similar public comparables like OPKO Health, Diagnósticos da América, Clinica Baviera, Castle Biosciences and more.
Novogene Overview
About Novogene
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
Founded
2011
HQ
Employees
N/A
Website
Financials (LTM)
EV
$655M
Novogene Financials
Novogene reported last 12-month revenue of $336M and EBITDA of $52M.
In the same LTM period, Novogene generated $52M in EBITDA and $27M in net income.
Revenue (LTM)
Novogene P&L
In the most recent fiscal year, Novogene reported revenue of $324M and EBITDA of $50M.
Novogene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $336M | XXX | $324M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $138M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $52M | XXX | $50M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $27M | XXX | $24M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Novogene Stock Performance
Novogene has current market cap of $883M, and enterprise value of $655M.
Market Cap Evolution
Novogene's stock price is $2.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $655M | $883M | -0.0% | XXX | XXX | XXX | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNovogene Valuation Multiples
Novogene trades at 2.0x EV/Revenue multiple, and 12.7x EV/EBITDA.
EV / Revenue (LTM)
Novogene Financial Valuation Multiples
As of April 22, 2026, Novogene has market cap of $883M and EV of $655M.
Equity research analysts estimate Novogene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novogene has a P/E ratio of 33.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $883M | XXX | $883M | XXX | XXX | XXX |
| EV (current) | $655M | XXX | $655M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 12.7x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBIT | 21.2x | XXX | 23.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.7x | XXX | XXX | XXX |
| P/E | 33.1x | XXX | 36.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 39.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Novogene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Novogene Margins & Growth Rates
Novogene's revenue in the last 12 month grew by 11%.
Novogene's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novogene's rule of X is 45% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Novogene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 45% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Novogene Public Comps
See public comps and valuation multiples for other Laboratory Services and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Novogene | XXX | XXX | XXX | XXX | XXX | XXX |
| OPKO Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagnósticos da América | XXX | XXX | XXX | XXX | XXX | XXX |
| Clinica Baviera | XXX | XXX | XXX | XXX | XXX | XXX |
| Castle Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Bioperfectus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novogene M&A Activity
Novogene acquired XXX companies to date.
Last acquisition by Novogene was on XXXXXXXX, XXXXX. Novogene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Novogene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNovogene Investment Activity
Novogene invested in XXX companies to date.
Novogene made its latest investment on XXXXXXXX, XXXXX. Novogene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Novogene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Novogene
| When was Novogene founded? | Novogene was founded in 2011. |
| Where is Novogene headquartered? | Novogene is headquartered in China. |
| Is Novogene publicly listed? | Yes, Novogene is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Novogene? | Novogene trades under 688315 ticker. |
| When did Novogene go public? | Novogene went public in 2021. |
| Who are competitors of Novogene? | Novogene main competitors are OPKO Health, Diagnósticos da América, Clinica Baviera, Castle Biosciences. |
| What is the current market cap of Novogene? | Novogene's current market cap is $883M. |
| What is the current revenue of Novogene? | Novogene's last 12 months revenue is $336M. |
| What is the current revenue growth of Novogene? | Novogene revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Novogene? | Current revenue multiple of Novogene is 2.0x. |
| Is Novogene profitable? | Yes, Novogene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Novogene? | Novogene's last 12 months EBITDA is $52M. |
| What is Novogene's EBITDA margin? | Novogene's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Novogene? | Current EBITDA multiple of Novogene is 12.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.